China’s drug industry pivots to AI-powered candidates to drive next wave of deals
After China’s cross-border deals for innovative drugs hit a record US$110 billion in the first half of 2026, the sector is now pivoting towards artificial intelligence-powered candidates to drive the…
Read the full articleYou might also wanna read
China’s drug industry pivots to AI-powered candidates to drive next wave of deals
After China’s cross-border deals for innovative drugs hit a record US$110 billion in the first half of 2026, the sector is now pivoting towa
China innovative drug out-licensing deal value reaches new high in first half of 2026, says CCTV
SHANGHAI, July 13 (Reuters) - The value of China's innovative drug out-licensing deals reached about $110 billion between January and June,
China innovative drug out-licensing deal value reaches new high in first half of 2026, says CCTV
SHANGHAI, July 13 (Reuters) - The value of China's innovative drug out-licensing deals reached about $110 billion between January and June,
Pharma’s AI Boom Has Bet on the Wrong Bottleneck
Investors have poured billions into using artificial intelligence to discover new drugs, and 2026 is the first real test of whether AI-desig
Senate bill seeks to curb US reliance on China in drug industry
US lawmakers are pushing for more scrutiny of Chinese investment in pharmaceuticals and biotechnology, as Washington’s strategic competition
China’s Chemical Industry Is Upgrading — And the R&D Gap Is Showing
China's chemical industry is shifting from volume to value. Discover how AI and formulation data infrastructure are driving the specialty ch
Comments
Sign in to join the conversation.
No comments yet. Be the first.